Joerg Krueger - Concepedia

Author

Joerg Krueger

Hospital for Sick Children ORCID

Also Known As

J KRUEGER, J Krueger, J. Krueger, Joerg Krueger, Jörg A. Krüger, Jörg Krüger, Krueger, J.

103

Publications

7.6K

Citations

H-Index

Concepts

All Affiliations

Hospital for Sick Children University of Toronto SickKids Foundation Hospital Sant Joan de Déu Barcelona Oslo University Hospital

About

Joerg Krueger is an author at Hospital for Sick Children specializing in medicine, immunology, and cell transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	250
2	Health Sciences	5	5	114
3	Blood Transplantation	3	3	60
4	Allergy	2	2	48
5	Cell Biology	2	2	34

Joerg Krueger

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, New England Journal of Medicine	2018	5.4K
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency Éric Bouffet, Valérie Larouche, Brittany Campbell, Journal of Clinical Oncology	2016	847
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial Theodore W. Laetsch, Shannon L. Maude, Susana Rives, Journal of Clinical Oncology	2022	314
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia Stephan A. Grupp, Shannon L. Maude, Susana Rives, Blood	2018	91
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Stephan A. Grupp, Theodore W. Laetsch, Jochen Buechner, Blood	2016	80
Significant Transplantation-Related Mortality from Respiratory Virus Infections within the First One Hundred Days in Children after Hematopoietic Stem Cell Transplantation Sakara Hutspardol, Mohammed Al Essa, Susan E. Richardson, Biology of Blood and Marrow Transplantation	2015	60
Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada Jill Furzer, Sumit Gupta, Paul C. Nathan, JAMA Oncology	2020	52
Vaccination against TIE2 reduces atherosclerosis Arnaud D. Hauer, Kim L. L. Habets, Eva J.A. van Wanrooij, Atherosclerosis InflammationVascular DiseaseImmunologyEndothelial DysfunctionVascular Biology	2008	37
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia Alan S. Wayne, Van Huynh, Nobuko Hijiya, Haematologica Cell TherapyMixed-phenotype Acute LeukemiaImmunodeficienciesImmunologyPathology	2022	37
S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY Susana Rives, Shannon L. Maude, H. Hiramatsu, HemaSphere Clinical ImmunologyMixed-phenotype Acute LeukemiaImmunodeficienciesFinal AnalysesImmunology	2022	35

Page 1